Convenient preparation of 4-aryl-2-(heteroarylamino)pyrimidines and 4-anilino-2-(heteroarylamino)pyrimidines

Tetrahedron Letters

Volumn 51, Issue 25, 2010, Pages 3259-3262

  Bliss, Brian I ^a   Ahmed, Feryan ^a   Iyer, Subashree ^a   Lin, Weimin ^a   Walker, Joel ^a   Zhao, He ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ANILINO 2 (HETEROARYLAMINO)PYRIMIDINE; 4 ARYL 2 (HETEROARYLAMINO)PYRIMIDINE; N 2 (6 METHOXYPYRIMIDIN 3 YL) N 4 PHENYLPYRIMIDINE 2,4 DIAMINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ARYLATION; DRUG SYNTHESIS; MICROWAVE RADIATION; SUBSTITUTION REACTION; TEMPERATURE;

EID: 77953121379     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2010.04.062     Document Type: Article

References (42)

1. DAPY is a commonly used abbreviation in the literature for 2,4-dianilinopyrimidines.
2. For lead articles on the topic of Privileged Structures, see:. Evans B.E., Rittle K.E., Bock M.G., DiPardo M.R., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., and Anderson P.S. J. Med. Chem. 31 (1988) 2235-2246
3. Müller G. Drug Discovery Today 8 (2003) 681-691
4. Smythe M.L., Horton D.A., and Bourne G.T. Chem. Rev. 103 (2003) 893-930
5. Bondensgaard K., Ankersen M., Thogersen H., Hansen B.S., Wulff B.S., and Bywater R.P. J. Med. Chem. 47 (2004) 888-899
6. DeSimone R.W., Currie K.S., Mitchell S.A., Darrow J.W., and Pippin D.A. Comb. Chem. High Throughput Screening 7 (2004) 473-493
7. Player M.R., Arvanitis E.A., Chadha N., and Rottorf R.S. J. Comb. Chem. 6 (2004) 414-419
8. Harris P.A., Boloor A., Cheung M., Kumar R., Crosby R.M., Davis-Ward R.G., Epperly A.H., Hinkle K.W., Hunter III R.N., Johnson J.H., Knick V.B., Laudeman C.P., Luttrell D.K., Mook R.A., Nolte R.T., Rudolph S.K., Szewczyk J.R., Truesdale A.T., Veal J.M., Wang L., and Stafford J.A. J. Med. Chem. 51 (2008) 4632-4640
9. De Clercq E. Expert Opin. Emerg. Drugs 10 (2005) 241-274
10. De Clercq E. Chem. Biodivers. 1 (2004) 44-64
11. Ludovici D.W., De Corte B.L., Kukla M.J.T., Ye H., Ho C.Y., Lichtenstein M.A., Kavash R.W., Andries K., de Béthune M.-P., Azijn H., Pauwels R., Lewi P.J., Heeres J., Loymans L.M.H., de Jonge M.R., Van Aken K.J.A., Daeyaert F.F.D., Das K., Arnold E., and Janssen P.A.J. Bioorg. Med. Chem. Lett. 11 (2001) 2235-2239
12. Guillemont J., Pasquier E., Palandjian P., Vernier D., Gaurrand S., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Daeyaert F.F.D., Vinkers M.H., Arnold E., Das K., Pauwels R., Andries K., de Béthune M.-P., Bettens E., Hertogs K., Wigerinck P., Timmerman P., and Janssen P.A.J. J. Med. Chem. 48 (2005) 2072-2079
13. Pytel D., Sliwinski T., Poplawski T., Ferriola D., and Majsterek I. Anti-Cancer Agents Med. Chem. 9 (2009) 66-76
14. Buchdunger E., and Capdeville R. Protein Tyrosine Kinases (2006) 145-160
15. Nadal E., and Olavarria E. Int. J. Clin. Pract. 58 (2004) 511-516
16. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Nat. Rev. Drug. Disc. 1 (2002) 493-502
17. Walker D.P., Bi F.C., Kalgutkar A.S., Bi F.C., Kalgutkar A.S., Bauman J.N., Zhao S.X., Soglia J.R., Aspnes G.E., Kung D.W., Klug-McLeod J., Zawistoski M.P., McGlynn M.A., Oliver R., Dunn M., Li J.-C., Richter D.T., Cooper B.A., Kath J.C., Hulford C.A., Autry C.L., Luzzio M.J., Ung E.J., Roberts W.G., Bonnette P.C., Buckbinder L., Mistry A., Giffor M.C., Han S., and Guzman-Perez A. Bioorg. Med. Chem. Lett. 18 (2008) 6071-6077
18. Yin J., Zhao M.M., Huffman M.A., and McNamara J.M. Org. Lett. 4 (2002) 3481-3484
19. Zhang H.Q., Xia Z., Vasudevan A., and Djuric S.W. Tetrahedron Lett. 47 (2006) 4881-4884
20. Krasavin M., Sandulenko Y., Komarov A., and Rufanov K. Tetrahedron Lett. 49 (2008) 5990-5993
21. Gong Y., and Pauls H.W. Synlett (2000) 829-831
22. Fleming, P. E.; Shi, Z.; Chen, S.; Schmidt, J. F.; Reader, J. C.; Hone, N. D.; Ciavarri, J. P. Preparation of aryl pyrimidines as protein kinase C inhibitors. WO 2005066139. January 10, 2005.
23. Okram, B.; Ren, P.; Gray, N. Preparation of pyrrolopyrimidines as protein kinase inhibitors. WO 2006124863A2, May 15, 2006.
24. Norman, M. H.; Pettus, L. H.; Wang, X.; Zhu, J. Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands. US 2006058308A1, September 13, 2005.
25. Andrews, D.; Finlay, M. R.; Green, C.; Clifford, J.; Oza, V. Imidazolo-5-yl-2-anilopyrimidines as agents for the inhibition of cell proliferation. WO 2006095159A1, March 8, 2005.
26. Singh, R.; Argade, A.; Payan, D. G.; Clough, J.; Keim, H.; Sylvain, C.; Li, H.; Bhamidipati, S. Methods of treating or preventing autoimmune diseases with 2,4-pyrimdinediamine compounds. WO 2004014382A1, February 19, 2004.
27. Ma H.-R., Wang Y.-Y., Liu P., Li D.-S., Shi Q.-Z., Lee G.-H., and Peng S.-M. Polyhedron 24 (2005) 215-220
28. Frolov A.N. Russ. J. Org. Chem. 42 (2006) 883-886
29. Luo G., Chen L., and Poindexter G.S. Tetrahedron Lett. 43 (2002) 5739-5742
30. For examples of 2-heteroarylaminopyrimidines prepared via alternate approaches to direct substitution of heteroarylamines onto 2-chloropyrimidines, see:. Schulte II J.P., and Tweedie S.R. Synlett (2007) 2331-2336
31. Guillaumet G., Garnier E., Audoux J., Pasquinet E., Suzenet F., Poullain D., and Lebret B. J. Org. Chem. 69 (2004) 7809-7815
32. Scott, D.; Wang, H., Wang, T. Preparation of pyrazolylamino substituted pyrimidines as anticancer agents. WO Patent 2006117560, November 11, 2006.
33. For an interesting discussion of the practical advantages of microwaves, see:. Kappe C.O., Herrero M.A., and Kremsner J.M. J. Org. Chem. 73 (2008) 36-47
34. + 294.1.
35. 9e
36. Louie J., and Hartwig J.F. Tetrahedron Lett. 36 (1995) 3609-3612
37. Guram A.S., Rennels R.A., and Buchwald S.L. Angew. Chem., Int. Ed. Engl. 34 (1995) 1348-1350
38. NAr conditions; see Ref. 9f.
39. Reactions were analyzed by LC-MS and complete conversion was generally observed after 4-6 h.
40. The surprising result reported for the formation of 16c (Table 2, entry 2) under microwave conditions is reproducible.
41. For information on the status of Dapivirine clinical trials, see: (a) International Partnerships for Microbicides (IPM). http://www.ipm-microbicides.org (accessed October 2009); (b) U.S. National Institutes of Health. http://clinicaltrials.gov (accessed October 2009).
42. Freyne, E. J. E.; Buijnsters, P. J. J. A.; Willems, M.; Embrechts, W. C. J.; Love, C. J.; Janssen, P. A. J.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Van Aken, K. J. A.; Diels, G. S. M. Heteroaryl amines as glycogen sythase kinase 3β inhibitors (GSK3 inhibitors). US 7514445 B2, April 7, 2009.